ChloroquineV1, Hal, Corpus, bibRecord, 000243

The treatment of rheumatoid arthritis during pregnancy

Identifieur interne : 000243 ( Hal/Corpus ); précédent : 000242; suivant : 000244

The treatment of rheumatoid arthritis during pregnancy

Auteurs : Rosamund Partlett ; Euthalia Roussou

Source :

Rheumatology International [ 0172-8172 ] ; 2010-12-01.

RBID : Hal:hal-00646916

English descriptors

mix :
- Pregnancy, Review, Rheumatoid arthritis, Treatment.

Abstract

There are a wide variety of medications available to treat patients with rheumatoid arthritis, many of which are considered unsafe during pregnancy. It is important to tailor a treatment regimen that stabilises the woman's disease prior to conception, using medications that are safe to continue throughout pregnancy and the post-partum period. Drugs that may be safely used during pregnancy include NSAIDs, corticosteroids, plus several DMARDs, including sulfasalazine and hydroxychloroquine. Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept.

Url:

https://hal.archives-ouvertes.fr/hal-00646916

DOI: 10.1007/s00296-010-1643-7

Links to Exploration step

Hal:hal-00646916

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The treatment of rheumatoid arthritis during pregnancy</title>
<author><name sortKey="Partlett, Rosamund" sort="Partlett, Rosamund" uniqKey="Partlett R" first="Rosamund" last="Partlett">Rosamund Partlett</name>
<affiliation><hal:affiliation type="institution" xml:id="struct-344447" status="VALID">          <orgName>Bart's and The London School of Medicine and Dentistry</orgName>
          <desc>            <address>              <addrLine>Queen Mary University of London Mile End Road London E1 4NS</addrLine>
              <country key="GB"></country>
            </address>
            <ref type="url">http://www.smd.qmul.ac.uk/</ref>
          </desc>
        </hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Roussou, Euthalia" sort="Roussou, Euthalia" uniqKey="Roussou E" first="Euthalia" last="Roussou">Euthalia Roussou</name>
<affiliation><hal:affiliation type="institution" xml:id="struct-344447" status="VALID">          <orgName>Bart's and The London School of Medicine and Dentistry</orgName>
          <desc>            <address>              <addrLine>Queen Mary University of London Mile End Road London E1 4NS</addrLine>
              <country key="GB"></country>
            </address>
            <ref type="url">http://www.smd.qmul.ac.uk/</ref>
          </desc>
        </hal:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:hal-00646916</idno>
<idno type="halId">hal-00646916</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-00646916</idno>
<idno type="url">https://hal.archives-ouvertes.fr/hal-00646916</idno>
<idno type="doi">10.1007/s00296-010-1643-7</idno>
<date when="2010-12-01">2010-12-01</date>
<idno type="wicri:Area/Hal/Corpus">000243</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The treatment of rheumatoid arthritis during pregnancy</title>
<author><name sortKey="Partlett, Rosamund" sort="Partlett, Rosamund" uniqKey="Partlett R" first="Rosamund" last="Partlett">Rosamund Partlett</name>
<affiliation><hal:affiliation type="institution" xml:id="struct-344447" status="VALID">          <orgName>Bart's and The London School of Medicine and Dentistry</orgName>
          <desc>            <address>              <addrLine>Queen Mary University of London Mile End Road London E1 4NS</addrLine>
              <country key="GB"></country>
            </address>
            <ref type="url">http://www.smd.qmul.ac.uk/</ref>
          </desc>
        </hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Roussou, Euthalia" sort="Roussou, Euthalia" uniqKey="Roussou E" first="Euthalia" last="Roussou">Euthalia Roussou</name>
<affiliation><hal:affiliation type="institution" xml:id="struct-344447" status="VALID">          <orgName>Bart's and The London School of Medicine and Dentistry</orgName>
          <desc>            <address>              <addrLine>Queen Mary University of London Mile End Road London E1 4NS</addrLine>
              <country key="GB"></country>
            </address>
            <ref type="url">http://www.smd.qmul.ac.uk/</ref>
          </desc>
        </hal:affiliation>
</affiliation>
</author>
</analytic>
<idno type="DOI">10.1007/s00296-010-1643-7</idno>
<series><title level="j">Rheumatology International</title>
<idno type="ISSN">0172-8172</idno>
<imprint><date type="datePub">2010-12-01</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="mix" xml:lang="en"><term>Pregnancy</term>
<term>Review</term>
<term>Rheumatoid arthritis</term>
<term>Treatment</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">              <p>There are a wide variety of medications available to treat patients with rheumatoid arthritis, many of which are considered unsafe during pregnancy. It is important to tailor a treatment regimen that stabilises the woman's disease prior to conception, using medications that are safe to continue throughout pregnancy and the post-partum period. Drugs that may be safely used during pregnancy include NSAIDs, corticosteroids, plus several DMARDs, including sulfasalazine and hydroxychloroquine. Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept.</p>
            </div>
</front>
</TEI>
<hal api="V3">          <titleStmt>            <title xml:lang="en">The treatment of rheumatoid arthritis during pregnancy</title>
            <author role="aut">              <persName>                <forename type="first">Rosamund</forename>
                <surname>Partlett</surname>
              </persName>
              <idno type="halauthorid">664969</idno>
              <affiliation ref="#struct-344447"></affiliation>
            </author>
            <author role="crp">              <persName>                <forename type="first">Euthalia</forename>
                <surname>Roussou</surname>
              </persName>
              <email type="md5">afce1ff199b1921ea9d734af13962764</email>
              <email type="domain">hotmail.com</email>
              <idno type="halauthorid">664970</idno>
              <affiliation ref="#struct-344447"></affiliation>
              <affiliation ref="#struct-175740"></affiliation>
            </author>
            <editor role="depositor">              <persName>                <forename>Hal</forename>
                <surname>Peer</surname>
              </persName>
              <email type="md5">86d0524708364ec39d879b6988476a91</email>
              <email type="domain">inria.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>            <edition n="v1" type="current">              <date type="whenSubmitted">2011-12-01 02:50:45</date>
              <date type="whenWritten">2010-05-05</date>
              <date type="whenModified">2011-12-01 02:50:45</date>
              <date type="whenReleased">2011-12-01 02:50:45</date>
              <date type="whenProduced">2010-12-01</date>
              <date type="whenEndEmbargoed">2011-12-01</date>
              <ref type="file" target="https://hal.archives-ouvertes.fr/hal-00646916/document">                <date notBefore="2011-12-01"></date>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://hal.archives-ouvertes.fr/hal-00646916/file/PEER_stage2_10.1007%252Fs00296-010-1643-7.pdf">                <date notBefore="2011-12-01"></date>
              </ref>
              <ref type="externalLink" target="https://hal.archives-ouvertes.fr/hal-00646916/document"></ref>
            </edition>
            <respStmt>              <resp>contributor</resp>
              <name key="148147">                <persName>                  <forename>Hal</forename>
                  <surname>Peer</surname>
                </persName>
                <email type="md5">86d0524708364ec39d879b6988476a91</email>
                <email type="domain">inria.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>            <distributor>CCSD</distributor>
            <idno type="halId">hal-00646916</idno>
            <idno type="halUri">https://hal.archives-ouvertes.fr/hal-00646916</idno>
            <idno type="halBibtex">partlett:hal-00646916</idno>
            <idno type="halRefHtml">Rheumatology International, Springer Verlag, 2010, 31 (4), pp.445-449. ⟨10.1007/s00296-010-1643-7⟩</idno>
            <idno type="halRef">Rheumatology International, Springer Verlag, 2010, 31 (4), pp.445-449. ⟨10.1007/s00296-010-1643-7⟩</idno>
          </publicationStmt>
          <seriesStmt>            <idno type="stamp" n="PEER">PEER Publishing and the Ecology of European Research</idno>
          </seriesStmt>
          <notesStmt>            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>            <biblStruct>              <analytic>                <title xml:lang="en">The treatment of rheumatoid arthritis during pregnancy</title>
                <author role="aut">                  <persName>                    <forename type="first">Rosamund</forename>
                    <surname>Partlett</surname>
                  </persName>
                  <idno type="halauthorid">664969</idno>
                  <affiliation ref="#struct-344447"></affiliation>
                </author>
                <author role="crp">                  <persName>                    <forename type="first">Euthalia</forename>
                    <surname>Roussou</surname>
                  </persName>
                  <email type="md5">afce1ff199b1921ea9d734af13962764</email>
                  <email type="domain">hotmail.com</email>
                  <idno type="halauthorid">664970</idno>
                  <affiliation ref="#struct-344447"></affiliation>
                  <affiliation ref="#struct-175740"></affiliation>
                </author>
              </analytic>
              <monogr>                <idno type="halJournalId" status="VALID">18719</idno>
                <idno type="issn">0172-8172</idno>
                <idno type="eissn">1437-160X</idno>
                <title level="j">Rheumatology International</title>
                <imprint>                  <publisher>Springer Verlag</publisher>
                  <biblScope unit="volume">31</biblScope>
                  <biblScope unit="issue">4</biblScope>
                  <biblScope unit="pp">445-449</biblScope>
                  <date type="datePub">2010-12-01</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1007/s00296-010-1643-7</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>            <langUsage>              <language ident="en">English</language>
            </langUsage>
            <textClass>              <keywords scheme="author">                <term xml:lang="en">Review</term>
                <term xml:lang="en">Treatment</term>
                <term xml:lang="en">Pregnancy</term>
                <term xml:lang="en">Rheumatoid arthritis</term>
              </keywords>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">              <p>There are a wide variety of medications available to treat patients with rheumatoid arthritis, many of which are considered unsafe during pregnancy. It is important to tailor a treatment regimen that stabilises the woman's disease prior to conception, using medications that are safe to continue throughout pregnancy and the post-partum period. Drugs that may be safely used during pregnancy include NSAIDs, corticosteroids, plus several DMARDs, including sulfasalazine and hydroxychloroquine. Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept.</p>
            </abstract>
          </profileDesc>
        </hal>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Hal/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000243 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Hal/Corpus/biblio.hfd -nk 000243 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Hal
   |étape=   Corpus
   |type=    RBID
   |clé=     Hal:hal-00646916
   |texte=   The treatment of rheumatoid arthritis during pregnancy
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

The treatment of rheumatoid arthritis during pregnancy

The treatment of rheumatoid arthritis during pregnancy

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri